Pharma Industry News

Insulin glargine meets primary endpoint in Sanofi’s type 1 diabetes study

InRange is the first worldwide multicentre RCT to compare second generation basal insulinsOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]